Suppr超能文献

多种信号通路调节N-CoR和SMRT复合物的核受体募集。

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

作者信息

Lavinsky R M, Jepsen K, Heinzel T, Torchia J, Mullen T M, Schiff R, Del-Rio A L, Ricote M, Ngo S, Gemsch J, Hilsenbeck S G, Osborne C K, Glass C K, Rosenfeld M G, Rose D W

机构信息

Howard Hughes Medical Institute, Department and School of Medicine, University of California at San Diego, La Jolla, CA 92093-0648, USA.

出版信息

Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2920-5. doi: 10.1073/pnas.95.6.2920.

Abstract

Several lines of evidence indicate that the nuclear receptor corepressor (N-CoR) complex imposes ligand dependence on transcriptional activation by the retinoic acid receptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppressing a constitutive N-terminal, Creb-binding protein/coactivator complex-dependent activation domain. Functional interactions between specific receptors and N-CoR or SMRT corepressor complexes are regulated, positively or negatively, by diverse signal transduction pathways. Decreased levels of N-CoR correlate with the acquisition of tamoxifen resistance in a mouse model system for human breast cancer. Our data suggest that N-CoR- and SMRT-containing complexes act as rate-limiting components in the actions of specific nuclear receptors, and that their actions are regulated by multiple signal transduction pathways.

摘要

多条证据表明,核受体共抑制因子(N-CoR)复合物使视黄酸受体的转录激活依赖配体,并介导雌激素受体拮抗剂(如他莫昔芬)的抑制作用,抑制组成型N端、Creb结合蛋白/共激活因子复合物依赖性激活结构域。特定受体与N-CoR或SMRT共抑制因子复合物之间的功能相互作用受多种信号转导途径正向或负向调控。在人乳腺癌小鼠模型系统中,N-CoR水平降低与他莫昔芬耐药性的获得相关。我们的数据表明,含N-CoR和SMRT的复合物在特定核受体的作用中起限速成分的作用,且它们的作用受多种信号转导途径调控。

相似文献

引用本文的文献

3
TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha.TRIM33是雌激素受体α的协同调节因子。
Cancers (Basel). 2024 Feb 20;16(5):845. doi: 10.3390/cancers16050845.
4
Epigenetic factors in breast cancer therapy.乳腺癌治疗中的表观遗传因素。
Front Genet. 2022 Sep 23;13:886487. doi: 10.3389/fgene.2022.886487. eCollection 2022.
5
Exploring new pathways in endocrine-resistant breast cancer.探索内分泌抵抗性乳腺癌的新途径。
Explor Target Antitumor Ther. 2022;3(3):337-361. doi: 10.37349/etat.2022.00086. Epub 2022 Jun 20.
10
Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer.雌激素阳性乳腺癌内分泌耐药的分子机制。
Front Endocrinol (Lausanne). 2021 Mar 25;12:599586. doi: 10.3389/fendo.2021.599586. eCollection 2021.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验